Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma

Chin Clin Oncol. 2023 Oct;12(5):47. doi: 10.21037/cco-23-44. Epub 2023 Sep 4.

Authors

Dmitrii Shek¹, Golo Ahlenstiel¹

Affiliation

¹ Blacktown Clinical School, Western Sydney University, Sydney, NSW, Australia; Westmead Institute for Medical Research, Sydney, NSW, Australia; Blacktown Mt Druitt Hospital, Sydney, NSW, Australia.

PMID: 37691347
DOI: 10.21037/cco-23-44

No abstract available

Keywords: Immune-checkpoint inhibitors (ICIs); T cells; hepatocellular carcinoma (HCC); immune-related adverse events; liver cancer.

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized